Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Type of study
Language
Year range
1.
Acta méd. peru ; 34(1): 52-56, ene. 2017. ilus
Article in Spanish | LILACS | ID: biblio-989116

ABSTRACT

El linfoma de Burkitt que afecta a las amígdalas representa el 5% de los linfomas no Hodgkin primarios extranodales y ocurre usualmente en pacientes con VIH que presentan valores altos de CD4 y viremia crónica. Presentamos el caso de un varón de 37 años con diagnóstico de VIH menor de 1 año, irregular en la terapia antiretroviral combinada, que presentó una lesión ulcerada, necrótica en amígdala izquierda, y lesiones osteolíticas en calota craneana con compromiso de partes blandas a predominio occipital. En los exámenes auxiliares se halló un recuento de linfocitos CD4 de 50 cel/mm3 y carga viral de 1 250 000 copias/mL. La biopsia de amígdala fue compatible con Linfoma de Burkitt. El compromiso de calota craneana concomitante a este tumor es raro. Se inició quimioterapia con CODOX-M/IVAC (ciclofosfamida, vincristina, doxorrubicina, metotrexate + citarabina intratecal); sin embargo, a respuesta clínica fue desfavorable, a pesar de la supresión virológica posterior


Burkitt's lymphoma affecting the tonsils represents 5% of primary extranodal non-Hodgkin lymphomas and it usually occurs in HIV-infected patients with high CD4+ counts and chronic viremia. We report a case of a 37 year-old male diagnosed with HIV infection less than one year ago, who had irregular adherence to HAART. This patient presented with an ulcerated and necrotic lesion in the left tonsil, and he also had osteolytic lesions in the cranial vault, with involvement of the soft tissues, predominantly in the occipital area. His CD4+ count was 50 cells/mm3 and the viral load (HIV-RNA) was 1'250,000 copies/mL. The biopsy of tonsil was reported as compatible with Burkitt's lymphoma. The patient was started with chemotherapy using CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin and methotrexate + intrathecal cytarabine); however, the overall clinical response was poor despite the good virological suppression

SELECTION OF CITATIONS
SEARCH DETAIL